Cerenome (PSTV) Operating Expenses (2011 - 2026)
Plus Therapeutics (PSTV) posted quarterly Operating Expenses of $8.1 million for Q1 2026, up 77.3% year-over-year from $4.6 million in Q1 2025, and up 14.6% quarter-over-quarter from $7.1 million in Q4 2025.
Cerenome (PSTV) Operating Expenses (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Operating Expenses for 16 consecutive years, with $8.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 77.3% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $24.1 million (up 19.49% YoY), while the FY2025 annual figure was $20.5 million, changed 0.04% from the prior year.
- Operating Expenses improved to $8.1 million in Q1 2026 per PSTV's latest filing, from $7.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $8.1 million in Q1 2026 and bottomed at $2.9 million in Q2 2025.
- Historically, Operating Expenses has averaged $5.1 million across 5 years, with a median of $5.2 million in 2022.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 98.83% — and 2025, when it tumbled 41.16%.
- Plus Therapeutics' Operating Expenses stood at $5.7 million in 2022, then dropped by 9.65% to $5.2 million in 2023, then advanced by 2.73% to $5.3 million in 2024, then soared by 33.83% to $7.1 million in 2025, then climbed by 14.6% to $8.1 million in 2026.
- Business Quant data shows PSTV's Operating Expenses at $8.1 million in Q1 2026, $7.1 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 9.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.15 Mn |
| Dec 31, 2025 | 7.11 Mn |
| Sep 30, 2025 | 5.88 Mn |
| Jun 30, 2025 | 2.93 Mn |
| Mar 31, 2025 | 4.60 Mn |
| Dec 31, 2024 | 5.31 Mn |
| Sep 30, 2024 | 5.26 Mn |
| Jun 30, 2024 | 4.98 Mn |
| Mar 31, 2024 | 4.98 Mn |
| Dec 31, 2023 | 5.17 Mn |
| Sep 30, 2023 | 4.49 Mn |
| Jun 30, 2023 | 3.34 Mn |
| Mar 31, 2023 | 5.23 Mn |
| Dec 31, 2022 | 5.72 Mn |
| Sep 30, 2022 | 5.17 Mn |
| Jun 30, 2022 | 5.12 Mn |
| Mar 31, 2022 | 3.93 Mn |
| Dec 31, 2021 | 3.94 Mn |
| Sep 30, 2021 | 3.50 Mn |
| Jun 30, 2021 | 2.58 Mn |